Sunshine Biopharma Inc.: Form 10-Q for the period ended Mar 31, 2015
Filed with the SEC on May 7, 2015 and accepted by EDGAR at May 7, 2015, 16:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2015-01-01 to 2015-03-31 | $0 | us-gaap:SalesRevenueGoodsNet |
| Research and development | 3 months2015-01-01 to 2015-03-31 | $0 | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-01-01 to 2015-03-31 | −$124.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-01-01 to 2015-03-31 | $169.5k | us-gaap:InterestExpense |
| Net income | 3 months2015-01-01 to 2015-03-31 | −$294.4k | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2015-01-01 to 2015-03-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months2015-01-01 to 2015-03-31 | −$113.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2015-03-31 | $148.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-03-31 | $148.7k | us-gaap:AssetsCurrent |
| Total assets | At period end2015-03-31 | $148.7k | us-gaap:Assets |
| Total liabilities | At period end2015-03-31 | $379.2k | us-gaap:Liabilities |
| Shareholders' equity | At period end2015-03-31 | −$230.5k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001354488-15-002193. Last ingested by Listed: Nov 14, 2026, 19:46 ET. Listed shows no prices and gives no investment advice.